10-Q: Bakhu Holdings Faces Financial Strain, Seeks Capital

Bakhu Holdings, Corp. reports no revenue for the quarter ended October 31, 2024, with an accumulated deficit of over $51 million, highlighting significant going concern risks and a substantial need for external financing.

Summary

• Bakhu Holdings, Corp. reported no revenue for the three months ended October 31, 2024, similar to the prior year's period.
• The company incurred a net loss of $771,387 for the quarter, a decrease from $1,131,478 in the same period last year, primarily due to reduced stock-based compensation.
• As of October 31, 2024, the company had $14,035 in cash and cash equivalents, with total liabilities of $11,307,989 and a stockholders' deficit of $11,293,954.
• The company has an accumulated deficit of $51,682,544 since inception.
• Significant notes payable, including to related parties, total $8,234,943.
• Management estimates a need for approximately $8.5 million in external capital over the next 12 months to fund operations and laboratory work.
• The company acknowledges substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's continued lack of revenue, significant accumulated deficit, ongoing operational challenges, and substantial future capital requirements, all of which cast significant doubt on its ability to continue as a going concern.

Positives

• Net loss decreased to $771,387 for the three months ended October 31, 2024, from $1,131,478 in the prior year's period, mainly due to lower stock-based compensation expenses.
• Consulting fees, which include stock-based compensation, decreased to $488,983 from $692,606 year-over-year.
• The company has secured agreements for future funding and potential change of control, such as the Binding Heads of Agreement with PhytoCyte Pty Ltd., aimed at restoring regulatory compliance and providing capital.

Negatives

• No revenue was generated in the three months ended October 31, 2024, and no revenue is expected until a commercialization program is launched.
• The company has an accumulated deficit of $51,682,544 as of October 31, 2024.
• Total liabilities stand at $11,307,989, with a significant portion being notes payable to related parties ($7,687,627).
• Cash and cash equivalents were only $14,035 as of October 31, 2024.
• The company defaulted on a settlement agreement with its landlord, VO Leasing Corp., and abandoned its laboratory facility.
• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is contingent upon obtaining capital through equity or debt issuance and achieving profitable operations.
• There is substantial doubt about the company's ability to continue as a going concern due to accumulated losses and anticipated future losses.
• The company estimates it will require approximately $8.5 million in external capital over the next 12 months, with no current commitments or agreements in place.
• Any future financing through debt or equity issuance could result in substantial dilution to existing stockholders.
• The company faces risks related to the ongoing Ukrainian Crises and potential 2026 Iran War, which could disrupt commercialization efforts.
• The company has experienced significant management and director resignations, leading to a cessation of operations and suspension of commercialization efforts.
• The company is subject to risks associated with its reliance on intellectual property licenses and potential disputes with licensors, such as Cell Science Holding Ltd.

Future Outlook

The company anticipates needing approximately $8.5 million in external capital over the next 12 months to fund laboratory work and general corporate operations. Commercialization efforts are dependent on securing sufficient funding, and the company cannot assure that such financing will be available or on acceptable terms. Any future financing may result in substantial dilution to existing stockholders.

Management Comments

• "We have not generated any revenue to date, and consequently, its operations are subject to all risks inherent in establishing a new business enterprise."
• "The Company has incurred losses since inception resulting in an accumulated deficit of $51,682,544 as of October 31, 2024 and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern."
• "We generated no net revenues during the three months ended October 31, 2024 and 2023. We do not expect to generate revenues until we launch our proposed commercialization program. We cannot predict whether or when that may occur."
• "The decrease [in net loss] is the mainly the result of the decrease in stock based compensation and we did not expect a major change in our net loss as our operations remain relatively the same as the prior year."
• "Our ability to continue as a going concern is contingent upon our ability to obtain capital through the sale of equity or issuance of debt and ultimately attaining profitable operations."

Industry Context

StockSavvy.ai notes that Bakhu Holdings operates in the nascent and highly regulated cannabis technology sector. The company's struggles to generate revenue and its significant accumulated deficit are common challenges for early-stage companies in this industry, often requiring substantial external funding and facing complex licensing and regulatory hurdles. The recent management changes and operational cessation highlight the extreme capital intensity and execution risks inherent in this market.

Comparison to Industry Standards

• Companies in the cannabis technology sector that have successfully commercialized often demonstrate significant revenue generation within 3-5 years of initial licensing or development, which Bakhu Holdings has not achieved.
• Industry benchmarks for early-stage biotech or specialized technology firms typically involve securing Series A or B funding rounds in the tens of millions of dollars to support R&D and commercialization; Bakhu's estimated $8.5 million need over 12 months is substantial relative to its current cash position but may be insufficient for full-scale commercialization without further rounds.
• Competitors like Canopy Growth or Aurora Cannabis, while larger, have also faced periods of significant losses and restructuring, underscoring the volatile nature of the industry, though they have achieved substantial revenue milestones.

Management Changes

Corporate Governance

Legal Proceedings

• A minority stockholder of Mentone threatened litigation and filed a purported complaint in Cyprus against Bakhu Holdings, Corp., one of its prior directors, and one of its former directors and executive officers, alleging unlawful removal from the board and unauthorized agreements. The company believes the complaint is without merit and intends to defend vigorously.
• Cell Science Holding Ltd. and Inter-M Traders FZ LLE sent a Formal Notice of Breach, Misrepresentation, Demand for Preservation of Evidence, and Reservation of Rights, alleging Bakhu failed in development, validation, and commercialization of licensed technology, and that Peter Whitton misrepresented the technology's capabilities. The company believes these claims are without merit and intends to defend vigorously.

Related Party Transactions

• Notes payable to related parties total $7,687,627 as of October 31, 2024, including notes to Cell Science Holding Ltd. and The OZ Corporation.
• The company has an Office Cost Sharing Agreement with The OZ Corporation, paying $34,000 per month for shared office space.
• As of October 31, 2024, $1,511,000 was owed to The OZ Corporation for unpaid space sharing fees.
• Convertible Senior Secured Promissory Notes payable to OZ Company (related party) and third parties accrue interest at 13% and are convertible into common stock.
• Convertible Promissory Notes executed on July 14, 2025, with OZ Company ($64,691.50) and PhytoCyte Pty Ltd. ($78,924.72) to cover costs for bringing delinquent reports current.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises and the conversion of convertible notes.
• Existing shareholders' ownership percentage will be diluted to 30% upon satisfaction of the Compliance Restoration Milestone under the Binding Heads of Agreement with PhytoCyte.
• Creditors and vendors may experience delays in payment given the company's low cash position and ongoing financial difficulties.
• Employees and consultants may be impacted by the cessation of operations and suspension of commercialization efforts.

Next Steps

• Secure approximately $8.5 million in external capital over the next 12 months.
• Fund planned laboratory work to improve and customize licensed processes.
• Secure appropriate laboratory facilities and required equipment.
• Seek to commercialize the licensed technology through joint ventures, strategic partners, or sublicenses.
• Prepare and file delinquent SEC reports to restore the company's reporting position.
• Restore the company to active and good standing by paying necessary liabilities and expenses.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, a substantial accumulated deficit, critically low cash reserves, and significant going concern risks. The ongoing operational cessation, management instability, and substantial capital needs without secured funding make the stock highly speculative and unattractive for investment at this time.

Keywords

cannabinoids, bioreactor, intellectual property, going concern, capital raise, licensing agreement, stock-based compensation, accumulated deficit